MSA Team Works Toward Publications

March 16, 2020

MSA has submitted three manuscripts in high impact journals that report the results of pre-clinical experiments evaluating the pharmacokinetics (nasal absorption), pharmacodynamics (efficacy), and safety in support of Bryn Pharma’s goal to bring a cost-effective intranasal delivery system for patients with anaphylaxis to market.

MSA authors include Principals Dr. Kenneth Dretchen Ph.D., Zack Mesa, and Michael Mesa, along with MSA associate Matt Robben Ph.D.

MSA News

Internship Experience Reflection – Kaitlyn Wylie

I never thought my first job would be in the biotechnology and pharmacy industry, let alone with such a passionate…

Read More

MesaGreen Pharmaceutical Company Files an Investigational New Animal Drug Application

FREDERICK, MD.  Nov. 10, 2022—MesaGreen Pharmaceutical Company announced today that the company has filed an Investigational New Animal Drug (INAD)…

Read More

Mesa Science Associates Receives Grant to Begin Study of a Treatment for Marfan Syndrome

Mesa Science Associates Inc. (MSA) received a Phase I Small Business Innovative Research Grant (SBIR) from the National Institutes of…

Read More